Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas BioPharma Holdings, Inc. develops biopharmaceutical therapies using its lipid nanocrystal, or LNC, delivery technology. Company updates center on MAT2203, an oral formulation of amphotericin B for invasive fungal infections, along with broader LNC platform applications for intracellular delivery of small molecules and oligonucleotides.
Recurring MTNB news also covers operating and financial results, clinical and regulatory disclosures, governance changes, shareholder ownership activity, capital-structure matters, and NYSE American continued-listing compliance. The company’s announcements connect its drug-development work with board oversight, financing needs, and public-company requirements.
Matinas BioPharma (MTNB) announced positive results from the EnACT trial of MAT2203 for treating cryptococcal meningitis. Early Fungicidal Activity (EFA) reached 0.38 log10 CFU/mL/day, surpassing the target of >0.20, indicating effective fungal clearance. A 95% overall survival rate was observed in Cohort 2 with no breakthrough infections. MAT2203 showed no kidney toxicity or electrolyte issues during 6 weeks of treatment. The Data Safety Monitoring Board supports advancing to Cohort 3, with enrollment underway, and the company plans to seek FDA engagement for early approval.
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) announced a Notice of Allowance from the USPTO for its oral formulation MAT2203, an antifungal medicine. This patent, covering a combination of amphotericin B and additional antifungal agents for treating central nervous system infections, extends patent protection to 2037. The company now holds six issued U.S. patents and 25 patents for its lipid nanocrystal platform, enhancing MAT2203's commercial potential. MAT2203 is currently in a Phase 2 clinical trial for cryptococcal meningitis in HIV patients, with further studies expected.
Matinas BioPharma Holdings, Inc. (MTNB) announced the completion of patient enrollment in the second cohort of the EnACT study for MAT2203, targeting cryptococcal meningitis, with data review expected in September 2021. Positive FDA feedback has enabled the initiation of a Phase 1 study for MAT2501, anticipated in Q4 2021. In vitro studies of lipid nanocrystal formulations of remdesivir show enhanced efficacy compared to traditional forms. Financially, cash reserves stood at approximately $59.8 million, providing operational support into 2024, with a reduced net loss of $5 million in Q2 2021.
Matinas BioPharma (MTNB) announced CEO Jerome D. Jabbour will participate in the BTIG Virtual Biotechnology Conference on August 10, 2021, at 3:00 p.m. ET. The company will also hold investor meetings during this event. Matinas focuses on enhancing drug delivery through its lipid nanocrystal (LNC) technology, which aims to overcome complex delivery challenges for therapeutics. Their lead candidates include MAT2203, an oral antifungal for cryptococcal meningitis, and MAT2501, an oral antibiotic for bacterial infections, both nearing significant clinical milestones.
Matinas BioPharma (NYSE: MTNB) announced a conference call on August 10, 2021, at 8:00 a.m. ET to discuss Q2 2021 operational and financial results. The call can be accessed by dialing (877) 407-5976 or through the company's website. Matinas is focused on enhancing drug delivery through its lipid nanocrystal (LNC) technology, with key products in development, including MAT2203 for cryptococcal meningitis and MAT2501 for bacterial infections. The company aims to address significant challenges in intracellular drug delivery, showing promise in various therapeutic areas.
Matinas BioPharma (MTNB) has announced a virtual R&D Day on June 17, 2021, at 8:30 a.m. ET, highlighting its lipid nanocrystal (LNC) delivery platform and pipeline programs. Key leaders, including Professors David Boulware and Peter Pappas, will provide clinical insights. The company is developing products like MAT2203 for cryptococcal meningitis and MAT2501 for nontuberculous mycobacterial lung infections, backed by funding from the Cystic Fibrosis Foundation. LYPDISO™ shows promising results in triglyceride management against Vascepa. A live Q&A session will follow the presentations.
Matinas BioPharma Holdings, Inc. (MTNB) reports Q1 2021 results with significant progress in clinical studies. Patient enrollment in the EnACT study for MAT2203, targeting cryptococcal meningitis, is at 70%, with a DSMB evaluation expected in Q3 2021. MAT2501 advances to preclinical studies, aiming for a Phase 1 study by year-end. Financially, cash reserves stand at $60.7 million, aiding operations into 2024. A net loss of $5.2 million was reported, unchanged from Q1 2020, while R&D expenses decreased to $3.2 million. Management remains optimistic about future developments and partnerships.
Matinas BioPharma (MTNB) announced that CEO Jerome D. Jabbour will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, at 11:20 a.m. ET. The company will also host investor meetings during the event. A live webcast of the presentation will be available on the company's website, with a replay accessible for 90 days. Matinas focuses on improving drug delivery through its lipid nanocrystal (LNC) platform and is developing multiple product candidates, including MAT2203 and MAT2501 for serious infections.
Matinas BioPharma Holdings (MTNB) will host a conference call on May 10, 2021, at 8:00 a.m. ET to discuss its Q1 2021 operational and financial results. The call can be accessed by dialing (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll), and will also be available via live webcast on the company's website. Matinas focuses on lipid nanocrystal technology for drug delivery, with ongoing studies for MAT2203, MAT2501, and LYPDISO, aimed at treating serious infections and cardiovascular conditions. Investors should note the inherent risks and uncertainties in their forward-looking statements.
Matinas BioPharma Holdings (MTNB) announced that CEO Jerome D. Jabbour will present an overview of the company at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 4:30 p.m. ET. The presentation will be available via live webcast on the company's investor relations page, with a replay accessible for 90 days. Matinas is focused on its innovative lipid nanocrystal delivery platform, developing products like MAT2203 for fungal infections and MAT2501 for bacterial infections, both in advanced clinical stages.